Less Bone Loss with Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study

Clinical Infectious Diseases

Volumn 61, Issue 7, 2015, Pages 1179-1188

  Taiwo, Babafemi O ^a   Chan, Ellen S ^b   Fichtenbaum, Carl J ^c   Ribaudo, Heather ^b   Tsibris, Athe ^d   Klingman, Karin L ^e   Eron, Joseph J ^f   Berzins, Baiba ^a   Robertson, Kevin ^g   Landay, Alan ^h   Ofotokun, Igho ⁱ   Brown, Todd ^j   Martinez, I ^k   Kalayjian, Robert ^k   Wilson, Cara ^k   Acosta, Edward ^k   Rusin, David ^k   Gonzales, Amy ^k   Roman, Orlando ^k   Melbourne, Kathy ^k   Rooney, James ^k   Reinhart, Alex ^k   Baugh, Bryan ^k   Qaqish, Roula ^k   Jayvant, Heera R ^k   Napolitano, Laura ^k   Walworth, Charles ^k   Petropoulos, Christos ^k   Davis, John ^k   Hite, Mark ^k   Seefried, Edward ^k   Benson, Constance ^k   Lambert, Nina ^k   Coleman, Karen ^k   James, Tamara ^k   Dill, Amy ^k   Baer, Jenifer ^k   Griesmer, Christine ^k   Basler, Cathi ^k   Bolivar, Hector ^k   Fischl, Margaret A ^k   Arduino, Roberto C ^k   Villamil, Aristoteles E ^k   Sha, Beverly ^k   Green, Tondria ^k   Jackson, Brenda ^k   Nicotera, Fred ^k   Kim, Geyoul ^k   Rodrieguez, Mark ^k   Luetkemeyer, Annie ^k   Dwyer, Jay ^k   Poethke, Pamela ^k   Rana, Aadia ^k   Chicurel Bayard, Miriam ^k   Telfer, Megan ^k   Van Dam, Cornelius ^k   Lane, Timothy ^k   Ofotokun, Ighovwerha ^k   Palmore, Melody ^k   Walton, Patricia ^k   Williams, Felicia ^k   Santana, Jorge L ^k   Mendez, Olga I ^k   Tebas, Pablo ^k   Thomas, Aleshia ^k   Flynn, Teri ^k   Sbrolla, Amy ^k   Landovitz, Raphael ^k   Cajahuaringa, Vanessa ^k   Dunaway, Shelia ^k   Storey, Sheryl ^k   Wiggins, Ilene ^k   Weiss, Andrea ^k   Reirden, Daniel ^k   Bernath, Hannah ^k   Yin, Michael ^k   Noel Connor, Jolene ^k   Kim, Rose ^k   Smith, Yolanda ^k   Sax, Paul ^k   Keenan, Cheryl ^k   Kumar, Princy ^k   Timpone, Joseph ^k   DubCrossed Dsign, Michael P ^k   Santos, Bartolo ^k   Adams, Mary ^k   Hurley, Christine ^k   more..

^a NORTHWESTERN UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f Departments of Infectious Diseases   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k NONE

more..

Author keywords

bone; darunavir; maraviroc; tenofovir

Indexed keywords

DARUNAVIR; EMTRICITABINE; MARAVIROC; PLACEBO; RITONAVIR; TENOFOVIR DISOPROXIL; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYCLOHEXANE DERIVATIVE; TENOFOVIR; TRIAZOLE DERIVATIVE;

ADULT; AFRICAN AMERICAN; ANTIVIRAL THERAPY; ARTICLE; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; GENOTYPE; HIP; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOLYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; VIRAL TROPISM; VIRUS LOAD; DRUG EFFECTS; HIV INFECTIONS; MIDDLE AGED; PELVIC GIRDLE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-HIV AGENTS; BONE DENSITY; CYCLOHEXANES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PELVIC BONES; TENOFOVIR; TRIAZOLES;

EID: 84942094407     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ455     Document Type: Article

References (42)

1. Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009; 27:817-24
2. van Vonderen MG, Lips P, van Agtmael MA, et al. First line zidovudine/ lamivudine/ lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 2009; 23:1367-76
3. McComsey GA, Kitch D, Daar E, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavirlamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791-801
4. Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51:554-61
5. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51:963-72
6. Gallant JE, Staszewski S, Pozniak AL, et al; 903 Study Group. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-treatment naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201
7. Moyle GJ, Stellbrink HJ, Compston J, et al. 96-week results of abacavir/ lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviralnaive, HIV-1-infected adults: ASSERT study. Antivir Ther 2013; 18:905-13
8. Huang JS, Hughes MD, Riddler SA, et al. Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. J Infect Dis 2011; 203:1791-801
9. Hansen AB, Obel N, Nielsen H, Pedersen C, Gerstoft J. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Med 2011; 12:157-65
10. Grant PM, Kitch D, McComsey GA. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis 2013; 57:1483-8
11. Gandhi RT, Spritzler J, Chan E, et al. Effect of baseline-and treatmentrelated factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1 positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 2006; 42:426-34
12. Grant PM, Komarrow L, Andersen J, et al. Risk analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One 2010; 5: e11416
13. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49:4721-32
14. Funderburg N, Kalinowska M, Eason J, et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS One 2010; 5:e13188
15. Wilkin TJ, Lalama CM, McKinnon J, et al. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4+T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis 2012; 206:534-42
16. Arberas H, Guardo AC, Bargalló ME, et al. In vitro effects of the CCR5 inhibitor maraviroc on human T cell function. J Antimicrob Chemother 2013; 68:577-86
17. Pozo-Balado MM, Martínez-Bonet M, Rosado I, et al. Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects. J Infect Dis 2014; 210:890-8
18. Hunt PW, Shulman NS, Hayes TL, et al. The immunologic effects ofmaraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. PLoS One 2013; 8:e80157
19. Yano S, Mentaverri R, Kanuparthi D, et al. Functional expression of beta-chemokine receptors in osteoblasts: role of regulated upon activation, normal T cell expressed and secreted (RANTES) in osteoblasts and regulation of its secretion by osteoblasts and osteoclasts. Endocrinology 2005; 146:2324-35
20. Han JH, Choi SJ, Kurihara N, et al. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001; 97:3349-53
21. Oba Y, Lee JW, Ehrlich LA, et al. MIP-1∞ utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exper Hematol 2005; 33:272-8
22. US Department of Health and Human Services. Drug interactions between CCR5 antagonists and other drugs. In: Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at: http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arvguidelines/288/ccr5-antagonist-drug-interactions. Accessed 27 January 2015.
23. Okoli C, Siccardi M, Thomas-William S, et al. Once daily maraviroc 300 mg or 150 mg in combination with DRV/r 800/100 mg. J Antimicrob Chemother 2012; 67:671-4
24. Abel S, Back DJ, Vourvahis M. Maraviroc: pharmacokinetics and drug interactions. Antivir Ther 2009; 14:607-18
25. Kakuda TN, Abel S, Davis J, et al. Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine and etravirine-darunavir ritonavir in healthy volunteers: results of two drug interaction trials. Antimicrob Agents Chemother 2011; 55:2290-6
26. McFadyen L, Jacqmin P, Wade J, et al. Maraviroc exposure-efficacy (50 copies/mL) analysis in HIV-1-infected treatment-naive subjects-ITT population (MERIT study) [abstract TUPE0053]. In: Program and abstracts of the XVII International AIDS Conference, Mexico City, 3-8 August 2008
27. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-41
28. National Osteoporosis Foundation. Clinician's guide to treatment and prevention of osteoporosis. Available at: http://nof.org/files/nof/public/content/file/344/upload/159.pdf. Accessed 28 January 2015
29. Sax PE, Saag MS, Yin MT, et al. Renal and bone safety of tenofovir alafenamide vs tenofovir disoproxil fumarate [abstract 143LB]. In: Program and abstracts of the 22nd Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 23-26 February 2015
30. Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Mansky KC. Tenofovir-associated bone density loss. Ther Clin Risk Manag 2010; 6:41-7
31. Havens PL, Kiser JJ, Stephensen CB, et al. Association of higher plasma vitamin d binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother 2013; 57:5619-28
32. Bianco C, Rossetti B, Gagliardini R, et al. Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/ 800/100 mg QD, preliminary results of GUSTA study. J Int AIDS Soc 2014; 17(4 suppl 3):19816
33. Kwan TS, Padrines M, Theoleyre S, Heymann D, Fortun Y. IL-6, RANKL, TNF alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004; 15:49-60
34. SiggelkowH, Eidner T, Lehmann G, et al. Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. J Bone Miner Res 2003; 18:529-38
35. Ding C, Parameswaran V, Udayan R, Burgess J, Jones G. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab 2008; 93:1952-8
36. Bedimo RJ, Maalouf NM, Zhang S, Dreschler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 2012; 26:825-31
37. Brown TT, Moser C, Currier JS, et al. Bone density changes after antiretroviral initiation with protease inhibitors or raltegravir [abstract 779LB]. In: Program and Abstract of the 21st Conference of Retroviruses and Opportunistic Infections, Boston, MA, 3-7 March 2014
38. Hoetelmans RM, Mariën K, De Pauw M, et al. Pharmacokinetic interaction between TMC 114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. Br J Clin Pharmacol 2007; 64:655-61
39. Jain RG, Lenhard JM. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem 2002; 277:19247-50
40. Wang MW, Wei S, Faccio R, et al. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest 2004; 114:206-13
41. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1, 25-dihydroxyvitamin D. AIDS 2003; 17:513-20
42. Stellbrink HJ, Pulik P, Szlavik J, et al. Maraviroc (MVC) dosed once daily with darunavir/ritonavir (DRV/r) in a 2 drug-regimen compared to emtricitabine/tenofovir (TDF/FTC) with DRV/r; 48-week results from MODERN (Study A4001095) [abstract TUAB0101]. In: Program and abstracts of the 20th International AIDS Conference, Melbourne, Australia, 20-25 July 2014